ZONISAMIDE (zonisamide) by Ichnos Glenmark Innovation is carbonic anhydrase inhibitors [moa]. First approved in 2006.
Drug data last refreshed 18h ago
Carbonic Anhydrase Inhibitors
Anti-epileptic Agent
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Zonisamide Outpatient Study
Zonisamide in Addition to E-CPT-C for Veterans With PTSD and Comorbid Alcohol Dependence
A Post-marketing Observational Study Of The Use Of Zonisamide (ZNS) in the Adjunctive Treatment Of Adult Patients With Partial Onset Seizures (Study E2090-E044-410) (ZOOM)
A Study to Evaluate the Safety and Efficacy of Zonisamide an Antiepileptic Drug as Monotherapy or Adjunctive Therapy in Treatment of Adult Patients With Partial, Generalized or Combined Seizures.
Zonisamide for the Treatment of Obstructive Sleep Apnea in Overweight/Obese Patients
Worked on ZONISAMIDE at Ichnos Glenmark Innovation? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.